A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults
- Registration Number
- NCT07235137
- Lead Sponsor
- Pfizer
- Brief Summary
A study to learn how the study medicine called Ibuzatrelvir is taken up into the blood in healthy Chinese adults.
- Detailed Description
To evaluate the PK profile of ibuzatrelvir after administration in Chinese healthy participants
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Ibuzatrelvir Ibuzatrelvir Ibuzatrelvir will be given by mouth to adult Chinese healthy volunteers
- Primary Outcome Measures
Name Time Method Maximum Observed Plasma Concentration (Cmax) up to Day 3 AUCinf up to Day 3 Terminal phase half-life (t½) up to Day 3
- Secondary Outcome Measures
Name Time Method Adverse events and severe adverse events up to Day 3 Incidence of abnormal and clinically relevant changes in vital signs up to Day 3 Incidence of abnormal and clinically relevant changes in electrocardiogram Up to Day 3 Incidence of abnormal and clinically relevant changes in laboratory assessments Up to Day 3
Trial Locations
- Locations (1)
Huashan Hospital, Fudan University
🇨🇳Shanghai, Shanghai Municipality, China
Huashan Hospital, Fudan University🇨🇳Shanghai, Shanghai Municipality, China